Literature DB >> 12438825

Mapping for ventricular tachycardia.

Sanjay Dixit1, David J Callans.   

Abstract

Mapping strategies for ventricular tachycardia (VT) have evolved significantly in the past 2 decades. This review discusses mapping techniques that can help in successful VT ablation. The electrocardiogram (ECG) remains a vital component of VT mapping and can help to identify the chamber of origin of VT. The ECG morphology of VT, however, is influenced by orientation of heart and location of the scar. Activation mapping during VT is an important technique that can help in further localization. Care has to be exercised to ensure that small signals are not ignored and far-field signals are recognized. Pace-mapping to mimic the VT is another way to map exit site for scar based reentrant VT or the site of origin of triggered and automatic VT in the absence of structural heart disease. For the latter group, this technique is widely used in determining the site of ablation. It is important to ensure a complete ECG match (12 out of 12 leads) of the pace-map to the clinical arrhythmia in these patients. In patients with structural heart disease, entrainment mapping remains the gold standard for defining the protected isthmus and other components of the VT circuit. Using this technique, successful ablation of reentrant VT can be achieved in 60-90% of patients. In order to perform entrainment mapping, the VT has to be hemodynamically tolerated; this is not the case in 25% of pts with scar based reentrant VT. The development of 3-dimensional mapping systems allows for more anatomically based linear ablation in patients with poorly tolerated uniform VT. Despite these advances, there are still about 10-20% VTs that cannot be ablated successfully with the above described techniques, especially in patients with structural heart disease. Other recent advances such as percutaneous closed chest epicardial mapping technique and cooled tip ablation catheter technology have the potential to enhance mapping and successful ablation of VT.

Entities:  

Mesh:

Year:  2002        PMID: 12438825     DOI: 10.1023/a:1021196627551

Source DB:  PubMed          Journal:  Card Electrophysiol Rev        ISSN: 1385-2264


  5 in total

Review 1.  Electrocardiologic and related methods of non-invasive detection and risk stratification in myocardial ischemia: state of the art and perspectives.

Authors:  Thomas Huebner; Matthias Goernig; Michael Schuepbach; Ernst Sanz; Roland Pilgram; Andrea Seeck; Andreas Voss
Journal:  Ger Med Sci       Date:  2010-10-11

2.  Detection of the diastolic pathway, circuit morphology, and inducibility of human postinfarction ventricular tachycardia from mapping in sinus rhythm.

Authors:  Edward J Ciaccio; Anthony W Chow; Riyaz A Kaba; D Wyn Davies; Oliver R Segal; Nicholas S Peters
Journal:  Heart Rhythm       Date:  2008-04-12       Impact factor: 6.343

3.  Prospective Assessment of an Automated Intraprocedural 12-Lead ECG-Based System for Localization of Early Left Ventricular Activation.

Authors:  Shijie Zhou; Amir AbdelWahab; B Milan Horáček; Paul J MacInnis; James W Warren; Jason S Davis; Ihab Elsokkari; David C Lee; Ciorsti J MacIntyre; Ratika Parkash; Chris J Gray; Martin J Gardner; Curtis Marcoux; Rajin Choudhury; Natalia A Trayanova; John L Sapp
Journal:  Circ Arrhythm Electrophysiol       Date:  2020-06-15

4.  Trend and risk factors of recurrence and complications after arrhythmias radiofrequency catheter ablation: a nation-wide observational study in Taiwan.

Authors:  Yuan Lin; Hsin-Kuan Wu; Te-Hsiung Wang; Tien-Hsing Chen; Yu-Sheng Lin
Journal:  BMJ Open       Date:  2019-05-30       Impact factor: 2.692

5.  Assessment of an ECG-Based System for Localizing Ventricular Arrhythmias in Patients With Structural Heart Disease.

Authors:  Shijie Zhou; Amir AbdelWahab; John L Sapp; Eric Sung; Konstantinos N Aronis; James W Warren; Paul J MacInnis; Rushil Shah; B Milan Horáček; Ronald Berger; Harikrishna Tandri; Natalia A Trayanova; Jonathan Chrispin
Journal:  J Am Heart Assoc       Date:  2021-10-06       Impact factor: 5.501

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.